High nuclear MSK1 is associated with longer survival in breast cancer patients.

High nuclear MSK1 is associated with longer survival in breast cancer patients. J Cancer Res Clin Oncol. 2018 Jan 11;: Authors: Pu X, Storr SJ, Ahmad NS, Rakha EA, Green AR, Ellis IO, Martin SG Abstract PURPOSE: Mitogen- and stress-activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase (MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 being suggested to potentially play a role in breast cancer cell proliferation, cell cycle progression, cell migration, invasion and tumour growth. The aim of the current study was to assess MSK1 protein expression in breast cancer tumour specimens, evaluating its prognostic significance. METHODS: A large cohort of 1902 early stage invasive breast cancer patients was used to explore the expression of MSK1. Protein expression was examined using standard immunohistochemistry on tissue microarrays. RESULTS: Low MSK1 protein expression was associated with younger age (P = 0.004), higher tumour grade (P 
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research

Related Links:

Condition:   Breast Cancer Intervention:   Drug: apatinib+oral etoposide Sponsor:   Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Giordano SH, Elias AD, Gradishar WJ Abstract The emergence of CDK4/6 inhibitors has changed the treatment algorithm for advanced/metastatic estrogen receptor-positive breast cancer. In pivotal trials of palbociclib, ribociclib, and abemaciclib, doubling in progression-free survival has been seen. All 3 agents in this class are now included in the NCCN Guidelines for Breast Cancer, and clinicians should be incorporating these agents into their treatment algorithms. The other important issue in this breast cancer setting is extended duration of endocrine therapy. Most of the benefit is modest and toxicity is...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Publication date: April 2018 Source:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1869, Issue 2 Author(s): S. O'Grady, M.P. Morgan The implementation of mammographic screening programmes in many countries has been linked to a marked increase in early detection and improved prognosis for breast cancer patients. Breast tumours can be detected by assessing several features in mammographic images but one of the most common are the presence of small deposits of calcium known as microcalcifications, which in many cases may be the only detectable sign of a breast tumour. In addition to their efficacy in the det...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
AbstractSB3 (Ontruzant®) is the first biosimilar of the reference anti-HER2 antibody trastuzumab to be approved in the EU. It is approved for use in all indications for which reference trastuzumab is approved, namely HER2-positive early breast cancer, metastatic breast cancer and metastatic gastric cancer. SB3 has similar physicochemical and pharmacodynamic properties to those of reference trastuzumab, and the pharmacokinetic biosimilarity of the agents has been shown in healthy volunteers and women with HER2-positive early or locally advanced breast cancer. SB3 demonstrated clinical efficacy considered equivalent to t...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
Conclusions: Patients who have had an axillary lymph node dissection and limited node-positive disease may be candidates for treatment with APBI. Further research is ultimately needed to better define specific criteria for APBI in node-positive patients.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
Condition:   Breast Neoplasms Interventions:   Drug: Denosumab 120 mg;   Drug: Denosumab 60 mg Sponsors:   Borstkanker Onderzoek Groep;   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Postmenopausal women with HR+/HER2- mBC who have previously failed an NSAI and received palbociclib+fulvestrant, everolimus+AI or everolimus+fulvestrant had longer PFS compared to those who received fulvestrant or AI alone. PMID: 29781326 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Condition:   Breast Neoplasms Interventions:   Drug: Denosumab 120 mg;   Drug: Denosumab 60 mg Sponsors:   Borstkanker Onderzoek Groep;   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The standard of care for HER2-positive breast cancer is trastuzumab (Herceptin) for a year; but could half that be enough?Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
M árcio Debiasi, Carisi A. Polanczyk, Patrícia Ziegelmann, Carlos Barrios, Hongyuan Cao, James J. Dignam, Paul Goss, Brittany Bychkovsky, Dianne M. Finkelstein, Rodrigo S. Guindalini, Paulo Filho, Caroline Albuquerque, Tomás Reinert, Evandro de Azambuja, Olufunmilayo Olopade
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Study